Qurient Co., Ltd.

Institut Pasteur Korea

Lead Discovery Center Gmbh

Jeongjun Kim

Jaeseung Kim

Kiyean Nam

SaeYeon Lee

Sangchul Lee

Sunhee Kang

Dongsik Park

Yeejin Jeon

Gahee Choi

Sung-Jun Han

Jiye Ahn

Young-In Yang

Doohyung Lee

Seohyun Ahn

Young Sam Park

Jinhwa Lee

Hana Kim

Jung Yoon Kim

Carsten Schultz-Fademrecht

Mooyoung Seo

Min Jung Seo

Zaesung No

Juhee Kang

Sumi Lee

Chun-won Jung

Minjung Seo

Jeongjea Seo

Yunmi Lee

Jung Hwan Kim

Chun-Won Jung

Yeong-In Yang

Ryang Yeo Kim

Kevin Pethe

Soohyun Oh

The present invention relates to benzimidazole derivatives having the general formula I, wherein n is 0 or 1; Xand Xare independently, at each occurrence, CRor N; Y is C-Calkylene, wherein alkylene is optionally substituted with one to two C-Calkyl groups; Ris selected from the group consisting of hydrogen, halogen, C-Calkoxy, &#x2014;NH, &#x2014;NHR, &#x2014;NRRand &#x2014;NH&#x2014;(R)&#x2014;R, n being 0 or 1; Ris selected from the group consisting of hydrogen, halogen, C-Calkyl, &#x2014;NH, &#x2014;NHR, &#x2014;NRRand &#x2014;NH&#x2014;(R)&#x2014;R; Ris selected from the group consisting of hydrogen, hydroxyl, OR, &#x2014;NRR, C-Calkoxy, C-Calkyl, C-Ccycloalkyl, C-Chaloalkyl, &#x2014;C(O)NHR, aryl, heteroaryl and heterocyclyl, wherein each of said cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four Rgroups; and Ris selected from the group consisting of &#x2014;NH, &#x2014;N(R)(V)R, &#x2014;NH(V)&#x2014;OR, &#x2014;NHC(O)R, and groups of formula 1a shown below, and their use in the treatment of diseases, in particular inflammatory diseases, cancer, stroke and/or Alzheimer's disease. 

2-amino-benzimidazole derivatives and their use as 5-lipoxygenase and/or prostaglandin E synthase inhibitors

The present invention relates to novel compounds which are inhibitors of TAM (Axl, Mer and Tyro 3) and/or Met family receptor tyrosine kinases (RTKs). These compounds are suitable for the treatment of disorders associated with, accompanied by, caused by or induced by a receptor of the TAM family, in particular a hyperfunction thereof. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly immune-suppressive cancer, refractory cancer and cancer metastases.

Quinoline derivatives as TAM RTK inhibitors

The present invention refers to: a compound having the general formula (I), wherein n is 0, 1, 2 or; m is 0, 1, 2 or 3; o is 0, 1, 2 or 3; W, X, Y and Z are independently selected from CH, N or N-oxide; A is NR, C&#x2550;O, C&#x2550;S, OP(O)(O), P&#x2550;O, CH2, or a heteroarly selected from the group consisting of (a), (b), (c), (d), (e), (f), (g); V is C&#x2550;O, O, S, CH, or NR; as well as its use in treating inflammatory diseases such as asthma, COPD, inflammation post infection, arthritis, atherosclerosis, pain and dermatitis. 

Anti-inflammation compounds

Growing community of inventors

Seoul, South Korea

Jeongjun Kim